Matching trials
2,411 results
- Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: Complete Statistical AnalysisIndependent statistical analysis of Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00944073).
- Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434330).
- Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01758588).
- Pembro/Carbo/Taxol in Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembro/Carbo/Taxol in Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02549209).
- Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02658019).
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02940496).
- Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: primary…
- Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02688608).
- Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02964559).
- Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02267603).
- Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02882282).
- Pembrolizumab in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02337686).
- Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy:…
- Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pemetrexed Plus Gemcitabine in Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Gemcitabine in Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00491075).
- Pento & tBUIndependent statistical analysis of Phase II Trial of Pentostatin and Targeted Busulfan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496340).
- Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PEPIIndependent statistical analysis of Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00578864).
- Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00059475).
- Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED): Complete Statistical AnalysisIndependent statistical analysis of Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Peripheral Dopamine in Postural Tachycardia Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Peripheral Dopamine in Postural Tachycardia Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00685919).
- PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00280735).
- Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: Complete Statistical AnalysisIndependent statistical analysis of Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00590902).
- Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pharmacokinetic Study of 4 mg Nicotine Lozenge.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Study of 4 mg Nicotine Lozenge.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01669122).
- Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00652028).
- Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pharmacokinetics of Advantage Anti-Caries Varnish: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Advantage Anti-Caries Varnish: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04183231).
- Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (MT-3724_NHL_003): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003): primary endpoint results, effect…